ArticleNature communications2014
A pan-cancer proteomic perspective on The Cancer Genome Atlas.
Erratum issuedAbstract read
In one paragraph
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 398 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
398citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
398 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visualization and Analysis in the Field of Pan-Cancer Studies and Its Application in Breast Cancer Treatment.Frontiers in medicine · 2021Pooled it
- Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.Signal transduction and targeted therapy · 2026Trial
- An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy.Cancer research · 2025Trial
- Trial
- Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites.Matrix biology : journal of the International Society for Matrix Biology · 2026Article
- NExON-Bayes: a Bayesian approach to network estimation informed by ordinal covariates.Bioinformatics (Oxford, England) · 2026Article
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.Developmental cell · 2026Article
- Spatially resolved proteomics provides insights into the normal-dysplasia-tumor continuum in oral squamous cell carcinoma.BMC oral health · 2026Article
- Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance.International journal of molecular sciences · 2026Review
- Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies Using a Bayesian Hierarchical Model.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- Metabolic pathway signatures define prognostic subtypes of lung adenocarcinoma.Discover oncology · 2026Article
- Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.Cell reports · 2026Article
- The expression landscape and clinical significance of cancer-specific RNA transcripts across human cancers.Journal of translational medicine · 2026Article
- Evaluating agentic AI for biological discovery in autonomous and copilot settings.bioRxiv : the preprint server for biology · 2026Article
- B.R.E.A.S.T. Breast canceR Enhanced AI-Supported Therapy: A New Interpretable Proteomics-Driven Machine Learning Framework for Therapy Response Prediction in Breast Cancer.International journal of molecular sciences · 2026Article
- Proteogenomic features define subtypes of mantle cell lymphoma.Blood advances · 2026Article
- Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice.Cancer research communications · 2026Article
- Article
- A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.Cell reports. Medicine · 2026Article
338 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
29 authors.
Rehan Akbani1] Department of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2].
Patrick Kwok Shing Ng1] Department of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2].
Henrica M J Werner1] Department of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, 5023 Bergen, Norway [3].
Maria ShahmoradgoliDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Fan ZhangDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Zhenlin JuDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Wenbin LiuDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Ji-Yeon Yang1] Department of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Applied Mathematics, Kumoh National Institute of Technology, Gumi 730-701, South Korea.
Kosuke YoshiharaDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Jun LiDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Shiyun LingDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Elena G SeviourDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Prahlad T RamDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
John D MinnaHamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, 1801 Inwood Rd, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
Lixia DiaoDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Pan TongDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Steven M HillMedical Research Council Biostatistics Unit, Cambridge CB2 0SR, UK.
Frank DondelingerMedical Research Council Biostatistics Unit, Cambridge CB2 0SR, UK.
Nicolas Städler1] Medical Research Council Biostatistics Unit, Cambridge CB2 0SR, UK [2] Department of Biochemistry, The Netherlands Cancer Institute, Postbox 90203, 1006 BE Amsterdam, The Netherlands.
Lauren A ByersDepartment of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Funda Meric-BernstamDepartment of Surgical Oncology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
John N Weinstein1] Department of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Department of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Bradley M BroomDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Roeland G W VerhaakDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Han LiangDepartment of Bioinformatics and Computational Biology, 1400 Pressler St., The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Sach Mukherjee1] Medical Research Council Biostatistics Unit, Cambridge CB2 0SR, UK [2] Cancer Research UK Cambridge Institute, School of Clinical Medicine, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK.
Yiling LuDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Gordon B MillsDepartment of Systems Biology, 1515 Holcombe Blvd, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MSystems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI GRAY, JOE W. · 2004 to 2014
$27.1MIntegrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)U24CA143883 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, MILLS, GORDON B. · 2009 to 2016
$10.6MBiological annotation of TCGA dataU01CA168394 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2012 to 2016
$4.7MLung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8MMedical Research Council MC_UP_1302/1NCI NIH HHS NCI P50CA70907NCI NIH HHS NCI U54 CA112970NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA100632NCI NIH HHS TCGA CA143883NCI NIH HHS U01 CA168394NCI NIH HHS U01 CA176284NCI NIH HHS U24 CA143883NCI NIH HHS U54 CA112970
Abstract
Protein levels and function are poorly predicted by genomic and transcriptomic analysis of patient tumours. Therefore, direct study of the functional proteome has the potential to provide a wealth of information that complements and extends genomic, epigenomic and transcriptomic analysis in The Cancer Genome Atlas (TCGA) projects. Here we use reverse-phase protein arrays to analyse 3,467 patient samples from 11 TCGA 'Pan-Cancer' diseases, using 181 high-quality antibodies that target 128 total proteins and 53 post-translationally modified proteins. The resultant proteomic data are integrated with genomic and transcriptomic analyses of the same samples to identify commonalities, differences, emergent pathways and network biology within and across tumour lineages. In addition, tissue-specific signals are reduced computationally to enhance biomarker and target discovery spanning multiple tumour lineages. This integrative analysis, with an emphasis on pathways and potentially actionable proteins, provides a framework for determining the prognostic, predictive and therapeutic relevance of the functional proteome.
Indexed as
Genome, HumanProteomicsCluster AnalysisErb-b2 Receptor Tyrosine KinasesGene DosageHumansNeoplasm ProteinsNeoplasmsOrgan SpecificityRNA, MessengerSignal TransductionStatistics, NonparametricERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesNeoplasm ProteinsRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.